This inventor holds 1 USPTO granted patent. Top assignee: Scandiedge Therapeutics Ab. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: Mathias Uhién: Innovator in Medical Treatments
Introduction
Mathias Uhién is a prominent inventor based in Stockholm, Sweden. He has made significant contributions to the field of medical treatments, particularly in addressing nonalcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC). His innovative approach has garnered attention in the medical community.
Latest Patents
Mathias Uhién holds a patent for a medical agent that targets PKLR inhibition in the treatment of NAFLD and HCC. This patent describes a method of treatment that utilizes a polynucleotide capable of silencing or knocking out the PKLR gene. This groundbreaking work has the potential to change the landscape of treatment options for these serious conditions.
Career Highlights
Uhién is associated with Scandiedge Therapeutics AB, where he continues to develop and refine his innovative medical solutions. His work is characterized by a commitment to advancing healthcare through scientific research and practical applications.
Collaborations
Mathias collaborates with notable professionals in his field, including Adil Mardinoglu and Jan Borén. These partnerships enhance the research and development efforts at Scandiedge Therapeutics AB, fostering an environment of innovation and discovery.
Conclusion
Mathias Uhién is a key figure in the development of new medical treatments, particularly for NAFLD and HCC. His contributions through patents and collaborations are paving the way for advancements in healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile